Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 710-713

  Johannessen, Svein I ^a  

^a National Center for Epilepsy   (Norway)

Author keywords

New antiepileptic drugs; Serum concentrations; Therapeutic drug monitoring

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; ALUMINUM; ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CIMETIDINE; ENZYME INDUCING AGENT; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LICARBAZEPINE; MAGNESIUM; NORCLOBAZAM; OXCARBAZEPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RIFAMPICIN; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

APLASTIC ANEMIA; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; EPILEPSY; HUMAN; INTOXICATION; LIVER DYSFUNCTION; LIVER TOXICITY; PATIENT CARE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; ARTICLE; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; PREDICTION AND FORECASTING; STANDARD;

ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; DRUG MONITORING; EPILEPSY; HUMANS; PREDICTIVE VALUE OF TESTS; REFERENCE STANDARDS; TREATMENT OUTCOME;

EID: 33646850091     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000179852.39717.3e     Document Type: Conference Paper

References (22)

1. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
2. Williams J, Bialer M, Johannessen SI, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia. 2003;44:40-45.
3. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42:1228-1255.
4. Armijo JA, Pena MA, Adin J, et al. Association between patient age and gabapentin serum concentrations-to-dose ratio: a preliminary multivariate analysis. Ther Drug Monit. 2004;26:633-637.
5. Gatti G, Ferrari AR, Guerrini R, et al. Plasma gabapentin concentrations in children witn epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit. 2003;25:54-60.
6. Lindberger M, Luhr O, Johannessen SI, et al. Serum concentration and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003;4:457-462.
7. Morris RG, Lee MY, Cleanthous X, et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit. 2004;26:626-632.
8. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (EILAT VII). Epilepsy Res. 2004;61:1-48.
9. May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit. 2003;25:690-699.
10. Contin M, Albani F, Riva R, et al. Levetiracetam therapeutic monitoring in patients with epilepsy and effect of concomitant antiepileptic drugs. Ther Drug Monit. 2004;26:375-379.
11. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit. 2005;27:199-204.
12. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13-18.
13. Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs. 2005;19:265-272.
14. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit. 2003;25:700-708.
15. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit. 2004;26:251-257.
16. Dahlin MG, Öhman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol. 2004;4:248-253.
17. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43:763-780.
18. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet. 2005;44:407-416.
19. Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure. 2004;13(Suppl 1):S17-S23.
20. Levy RH, Ragueneau-Majlessi I, Garnett WR, et al. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy. J Clin Pharmacol. 2004;44:1230-1234.
21. Levy RH, Ragueneau-Majlessi I, Brodie MJ, et al. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit. 2005;27:193-198.
22. Touw DJ, Neef C, Thomson AH. Cost-effectiveness of therapeutic drug monitoring. A systematic review. Ther Drug Monit. 2005;27:10-17.